Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | CA4 | P22748 | 8/20 | 0.53 |
| ▸ | CA7 | P43166 | 8/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.48 |
| ▸ | PAK3 | O75914 | 1/20 | 0.48 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 3/20 | 0.47 |
| ▸ | CCNC | P24863 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384698 | 0.93 | CDK8 (0.53) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2387043 | 0.84 | CDK8 (0.51) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2381611 | 0.80 | TRPV1 (0.57) | TRPV1KIT | |
| SCHEMBL2385230 | 0.80 | TRPV1 (0.57) | TRPV1KIT | |
| SCHEMBL2383360 | 0.80 | TRPV1 (0.52) | TRPV1KIT | |
| SCHEMBL2382762 | 0.79 | TRPV1 (0.55) | TRPV1F10EPHB4KIT | |
| SCHEMBL2382881 | 0.77 | PDE10A (0.53) | USP30 | |
| SCHEMBL2384912 | 0.77 | TRPV1 (0.49) | TRPV1KIT | |
| SCHEMBL2382673 | 0.75 | TRPV1 (0.42) | TRPV1F10EPHB4 | |
| SCHEMBL2383853 | 0.75 | LDHA (0.44) | TRPV1PAK1PAK3PAK2CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | CA12 2796/4885CA1 3906/4885CA2 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.